Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells.

por Somay, C., Grunt, T. W., Mannhalter, C., Dittrich, C.
Publicado 1992

Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels

por Czejka, M., Sahmanovic, A., Buchner, P., Steininger, T., Dittrich, C.
Publicado 2013

Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription.

por Harant, H., Korschineck, I., Krupitza, G., Fazeny, B., Dittrich, C., Grunt, T. W.
Publicado 1993

Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells.

por Krupitza, G., Grill, S., Harant, H., Hulla, W., Szekeres, T., Huber, H., Dittrich, C.
Publicado 1996

Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene.

por Krupitza, G., Fritsche, R., Dittrich, E., Harant, H., Huber, H., Grunt, T., Dittrich, C.
Publicado 1995

A phase I and pharmacokinetic study of indisulam in combination with carboplatin

por Dittrich, C, Zandvliet, A S, Gneist, M, Huitema, A D R, King, A A J, Wanders, J
Publicado 2007

The human tumour cloning assay in the management of breast cancer patients.

por Dittrich, C., Jakesz, R., Wrba, F., Havelec, L., Haas, O., Spona, J., Holzner, H., Kolb, R., Moser, K.
Publicado 1985

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research...

por Steinbild, S, Mross, K, Frost, A, Morant, R, Gillessen, S, Dittrich, C, Strumberg, D, Hochhaus, A, Hanauske, A-R, Edler, L, Burkholder, I, Scheulen, M
Publicado 2007

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

por Dittrich, C., Kosty, M., Jezdic, S., Pyle, D., Berardi, R., Bergh, J., El Saghir, N., Lotz, J.-P., Österlund, P., Pavlidis, N., Purkalne, G.
Publicado 2016

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central...

por Mross, K, Dittrich, C, Aulitzky, W E, Strumberg, D, Schutte, J, Schmid, R M, Hollerbach, S, Merger, M, Munzert, G, Fleischer, F, Scheulen, M E
Publicado 2012